tradingkey.logo

Ginkgo Bioworks Holdings Inc

DNA
查看详细走势图
8.405USD
-0.505-5.67%
收盘 12/26, 16:00美东报价延迟15分钟
477.71M总市值
亏损市盈率 TTM

Ginkgo Bioworks Holdings Inc

8.405
-0.505-5.67%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-5.67%

5天

+3.77%

1月

-7.74%

6月

-11.15%

今年开始到现在

-14.41%

1年

-12.99%

查看详细走势图

TradingKey Ginkgo Bioworks Holdings Inc股票评分

单位: USD 更新时间: 2025-12-26

操作建议

Ginkgo Bioworks Holdings Inc当前公司基本面数据相对稳定,增长潜力较大。当前估值合理,在生物技术与医疗研究行业排名181/404位。机构持股占比非常高,近一月多位分析师给出公司评级为卖出。最高目标价10.67。中期看,股价处于下降通道。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Ginkgo Bioworks Holdings Inc评分

相关信息

行业排名
181 / 404
全市场排名
319 / 4563
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 4 位分析师
卖出
评级
10.667
目标均价
+13.48%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Ginkgo Bioworks Holdings Inc亮点

亮点风险
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
估值合理
公司最新PE估值-1.36,处于3年历史合理位
机构减仓
最新机构持股31.33M股,环比减少0.01%
景顺投资公司持仓
明星投资者景顺投资公司持仓,最新持仓市值189.53K

Ginkgo Bioworks Holdings Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Ginkgo Bioworks Holdings Inc简介

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
公司代码DNA
公司Ginkgo Bioworks Holdings Inc
CEOKelly (Jason)
网址https://investors.ginkgobioworks.com/

常见问题

Ginkgo Bioworks Holdings Inc(DNA)的当前股价是多少?

Ginkgo Bioworks Holdings Inc(DNA)的当前股价是 8.405。

Ginkgo Bioworks Holdings Inc的股票代码是什么?

Ginkgo Bioworks Holdings Inc的股票代码是DNA。

Ginkgo Bioworks Holdings Inc股票的52周最高点是多少?

Ginkgo Bioworks Holdings Inc股票的52周最高点是17.580。

Ginkgo Bioworks Holdings Inc股票的52周最低点是多少?

Ginkgo Bioworks Holdings Inc股票的52周最低点是5.000。

Ginkgo Bioworks Holdings Inc的市值是多少?

Ginkgo Bioworks Holdings Inc的市值是477.71M。

Ginkgo Bioworks Holdings Inc的净利润是多少?

Ginkgo Bioworks Holdings Inc的净利润为-547.03M。

现在Ginkgo Bioworks Holdings Inc(DNA)的股票是买入、持有还是卖出?

根据分析师评级,Ginkgo Bioworks Holdings Inc(DNA)的总体评级为卖出,目标价格为10.667。

Ginkgo Bioworks Holdings Inc(DNA)股票的每股收益(EPS TTM)是多少

Ginkgo Bioworks Holdings Inc(DNA)股票的每股收益(EPS TTM)是-6.189。
KeyAI